Amphorna Biosciences is advancing a targeted RNA therapeutics platform powered by innovative delivery technologies. The platform is designed to generate repeatable product opportunities across fibrosis, oncology, and immunology rather than depend on a single asset.
We welcome collaboration across venture investment, pharmaceutical co-development, licensing, and strategic partnerships.
Partner with us to advance targeted RNA medicines.
Explore collaboration opportunities in targeted RNA therapeutics and platform expansion.
Partner with us to build the next generation of RNA medicines for high-value indications.
Co-develop breakthrough therapies and accelerate clinical development together.
Leverage our platform and IP to create value through licensing and strategic alliances.
Contact us to learn more about our platform, pipeline, and investment opportunities.
One shared platform generates multiple programs, spreading risk across a broad pipeline.
AOC-based approaches expand therapeutic opportunities for immune-related diseases and traditionally undruggable cancer targets.
Fibrosis indications including MASH/NASH, IPF, and CKD represent significant patient populations.